Perceptive Advisors LLC Neurocrine Biosciences Inc Transaction History

Perceptive Advisors LLC

$4.77 Billion
Q1 2024

A detailed history of Perceptive Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Perceptive Advisors LLC holds 804,409 shares of NBIX stock, worth $111 Million. This represents 2.33% of its overall portfolio holdings.

Number of Shares

804,409

Previous 270,794 197.06%

Holding current value

$111 Million

Previous $35.7 Million 210.95%

% of portfolio

2.33%

Previous 0.87%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $69.6 Million - $76.7 Million	533,615 Added 197.06%	804,409 $111 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $11.8 Million - $14.8 Million	111,552 Added 70.05%	270,794 $35.7 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $5.57 Million - $6.93 Million	59,192 Added 59.16%	159,242 $17.9 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $27.4 Million - $32.1 Million	-297,838 Reduced 74.85%	100,050 $10.6 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $170,451 - $225,057	2,249 Added 0.57%	397,888 $38.8 Million

Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $6.33 Million - $8.28 Million	-87,368 Reduced 18.09%	395,639 $37.1 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $28.3 Million - $32.6 Million	-328,825 Reduced 40.5%	483,007 $46.3 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $11.6 Million - $13.3 Million	-130,000 Reduced 13.8%	811,832 $79 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $83.8 Million - $114 Million	-957,383 Reduced 50.41%	941,832 $91.6 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $30.5 Million - $38 Million	350,500 Added 22.63%	1,899,215 $182 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $57 Million - $80.1 Million	-592,695 Reduced 27.68%	1,548,715 $149 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $78.4 Million - $120 Million	-921,853 Reduced 30.09%	2,141,410 $261 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $41.3 Million - $62.5 Million	-549,291 Reduced 15.21%	3,063,263 $265 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $38.8 Million - $53 Million	-447,346 Reduced 11.02%	3,612,554 $388 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $3.02 Million - $3.66 Million	36,038 Added 0.9%	4,059,900 $366 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $19.2 Million - $24.2 Million	265,200 Added 7.06%	4,023,862 $340 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $58.9 Million - $77.8 Million	-849,892 Reduced 18.44%	3,758,662 $331 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $11.5 Million - $21 Million	-168,700 Reduced 3.53%	4,608,554 $315 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $6.13 Million - $7.8 Million	62,004 Added 1.31%	4,777,254 $587 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $3.52 Million - $4.95 Million	-46,739 Reduced 0.98%	4,715,250 $463 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $29.6 Million - $36 Million	-389,600 Reduced 7.56%	4,761,989 $395 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $21.1 Million - $27.9 Million	360,000 Added 7.51%	5,151,589 $400 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $230 Million - $294 Million	4,791,589	4,791,589 $294 Million

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.

Account

Perceptive Advisors LLC Neurocrine Biosciences Inc Transaction History